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Summary:  Osteocalcin or bone gamma-carboxyglutamic acid (gla) protein and Bone-specific alkaline 
phosphatase (b-AP) total protein levels were evaluated as indicators of bone turnover in twenty patients 
with sickle cell haemoglobinopathies and in twenty normal healthy individuals. The serum bone-
specific alkaline phosphatase total protein level was measured by immunoradiometric (IRMA) method. 
The concentrations of serum bone-specific alkaline phosphatase total protein were higher in the study 
group than in the control group (p < 0.05). The serum osteocalcin (BGP) showed no significant 
difference with the control healthy subjects. There was no correlation between the serum osteocalcin 
and serum bone-specific alkaline phosphatase total protein in the patient group. In conclusion, serum 
bone-specific alkaline phosphatase total protein determined or measured by IRMA can be considered a 
sensitive marker of bone turnover and could be especially useful as valuable non-invasive biochemical 
marker for identifying sickle cell patients with bone complications. 
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Introduction
Sickle cell haemoglobinopathies are 
probably the commonest known hereditary 
blood disorders in Nigeria (David et al, 1993; 
Ballas, 1995). The sickle cell anaemia (SS) is 
the homozygous state in which the sickle gene 
is inherited from the father and the mother. 
Sickle cell disease may also occur in a 
heterozygous form in conjunction with other 
haemoglobin beta chair abnormalities. The 
common heterozygous forms include sickle 
haemoglobin C disease (HbSC), and sickle 
cell haemoglobin thalassaemia (HbS+thal. or 
HbSothal.) (David et al, 1993; Ballas, 1995; 
Ballas 2001; Smith, 1996; Aster, 2004; 
Iwegbu and Fleming 1985).
Sickle cell disorder may be classified as 
an uncompensated haemolytic anaemia in 
which the life span of the erythrocytes is 
shortened due to increased rate of destruction 
and this is insufficiently balanced by increase 
in erythropoiesis.  Vascular occlusion plays a 
major role in the clinical course of sickle cell 
disorders (Lee et al, 1981; Embury et al, 1994; 
Francis and Johnson, 1991; Hebbel, 1991; 
Powars, 1990). Vascular occlusion may occur 
in both the microcirculation and the 
macrocirculation. When vascular occlusion 
occurs in the microcirculation it leads to acute 
sickle cell painful episodes, which is the 
hallmark of the sickle cell disorder. Vascular
occlusion in the macrocirculation is associated 
organ failure (Lee et al, 1981; Embury et al,
1994; Francis and Johnson, 1991; Hebbel, 
1991; Powars, 1990). 
Patients with sickle cell disorders often 
suffer from both chronic haemolytic anaemia, 
which causes bone marrow hyperplasia (Lee et 
al, 1981; Embury et al, 1994; Francis and 
Johnson, 1991; Hebbel, 1991; Powars, 1990) 
and repeated episodes of vaso-occlusion (Lee 
et al, 1981; Embury et al, 1994; Francis and 
Johnson, 1991; Hebbel, 1991; Powars, 1990). 
The results of infection and infarction, which 
lead to orthopaedic complications, have been 
well documented by several authors (Lee et al, 
1981; Embury et al, 1994; Francis and 
Johnson, 1991; Hebbel, 1991; Powars, 1990). 
Avascular necrosis is the commonest and 
a major chronic complication of sickle cell 
disorders (David et al, 1993; Ballas, 1995; 
Ballas 2001; Smith, 1996; Mitchell et al, 1986; 
Rao et al, 1985; Rao et al, 1989; Amundsen et 
al, 1984; Milner et al, 1993; Mitchell et al
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1987). The sickle cell disease is a cause of hip 
deformities in the patients (David et al, 1993; 
Ballas, 1995; Ballas 2001; Smith, 1996; Lee, et 
al, 1981; Embury et al, 1994; Francis and 
Johnson, 1991; Hebbel, 1991; Powars, 1990). 
Involvement of the humeral head is also very 
common (Rao et al, 1985; Rao et al, 1989; 
Amundsen et al, 1984; Milner et al, 1993; 
Mitchell et al, 1987). More than 30 percent of 
patients with sickle cell disorders end up with 
complications of avascular necrosis of the 
bone (David et al, 1993; Ballas, 1995; Ballas 
2001; Smith, 1996). 
The disappointing results of treatment of 
avascular necrosis after bony collapse have led 
to the suggestion by many workers that future 
efforts should be directed to the early detection 
or diagnosis of this bone disease before the 
onset of the skeletal or structural failure in 
patients with sickle cell haemoglobinopathies. 
Bone scan with technetium 99mTc and magnetic 
resonance imaging (MRI) can detect disease 
but these tests are very expensive and difficult 
to use routinely in a developing country like 
Nigeria (David et al, 1993; Ballas, 1995; 
Ballas 2001; Smith, 1996; Rao et al, 1985; Rao 
et al, 1989; Amundsen et al, 1984; Milner et 
al, 1993; Mitchell et al, 1987). Recently there 
has been introduction of new biochemical 
markers of bone metabolism such as 
osteocalcin and others (Bettica and Moro, 
1995; Kleerekoper 1997; De la Piedra et al,
1996; Bolarin, 1996).
a.      Osteocalcin
Osteocalcin or bone gamma-
carboxyglutamic acid (gla) protein (BGP) is 
the most abundant non-collagenous protein 
found in bone (Bolarin, 1996). Osteocalcin has 
a molecular weight of 5.7 kD. It is synthesized 
exclusively by osteoblasts and by its dental 
form, the odontoblasts (Lian and Grundberg 
1988; Hauschka et al, 1989). Osteocalcin 
represents the activity of osteoblasts, since it is 
synthesized and released into circulation by the 
osteoblasts. The protein is eliminated by 
glomerular filtration and degraded by the renal 
tubule (Bolarin, 1996; Lian and Grundberg 
1988; Hauschka et al, 1989; Garnero et al,
1994). 
Measurement of osteocalcin is by 
immunoassays using monoclonal or polyclonal 
antibodies. It is advised that blood samples be 
collected in ice and plasma or serum is stored 
at –20 oC or –70 oC. It should be thawed once 
to prevent degradation of the protein (Bolarin, 
1996; Lian and Grundberg 1988; Hauschka et 
al, 1989; Garnero et al, 1994). 
b.     Alkaline phosphatase (EC. 3.1.3.1)
Bone-specific alkaline phosphatase (b-
AP) is a plasma membrane enzyme. For many 
years this enzyme has been the most 
commonly used biochemical marker to assess 
osteoblast function (Bolarin, 1996). Bone-
specific alkaline phosphatase activity 
correlates with bone formation rate in 
metabolic disease of the bone (Bolarin, 1996; 
Grundberg, 1993; Bolarin, 2001) and during 
normal physiological bone growth (Bolarin, 
1996; Grundberg, 1993; Bolarin, 2001). The 
serum alkaline phosphatase activity is present 
in tissues other than bone. The isoenzymes can 
be divided into four groups (placental, 
carcinoplacental, intestinal, and hepatic, renal, 
skeletal group). The major fraction of the total 
serum is from the liver and bone isoforms or 
isoenzymes, which are both products of the 
same genetic loci (Bolarin, 1996; Grundberg, 
1993; Bolarin, 2001). It is often difficult to 
distinguish between the two isoenzymes. But 
distinction is necessary for clinical use 
(Bolarin, 1996). 
There are several methods for the 
estimation of serum bone-specific alkaline 
phosphatase. These methods include 
inactivation some of the isoenzymes by heat or 
using chemical compounds, precipitation with 
wheat germ lectin and separation by 
electrophoresis. These techniques, however, do 
not seem to provide the sensitivity, specificity 
and reliability required for routine clinical use 
(Bolarin, 1996; Grundberg, 1993; Bolarin, 
2001). A two-site immunoradiometric assay 
that preferentially recognizes bone-specific 
alkaline phosphatase is generally being used in 
most clinical or research laboratories (Bolarin, 
1996; Grundberg, 1993; Bolarin, 2001). These 
new assay methods have shown improved 
diagnostic accuracy with regards to bone 
diseases and their therapeutic monitoring 
(Bolarin, 1996; Grundberg, 1993; Bolarin, 
2001).
In the present preliminary study, serum 
osteocalcin is assayed by enzyme 
immunoassay using monoclonal antibody.
Serum bone-specific alkaline phosphatase 
protein (b-AP) was also measured by 
immunoradiometric assay (IRMA). Both 
biochemical markers were used to investigate 
bone turnover in patients with sickle cell 
haemoglobinopathies. 
Materials And Methods 
Study Population 
Twenty patients consisted of 9 men 
and 11 women with sickle cell 
haemoglobinopathies. Mean age  standard 
deviation was 31.6  11.5 years (median 30 
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years, range 18 - 5 1 years). A reference 
control group of 20 apparently healthy 
subjects (9 males and 11 females), age range 
20 – 52 years (median 30 years). None of 
the persons had a history serious disease or 
was taking drugs known to affect bone 
metabolism or the blood vessels. The control 
had no history of fractures nor any 
nutritional, metabolic, liver, renal or bone 
disease. None of the females were on 
contraceptives prior to obtaining blood 
samples. All control subjects had 
haemoglobin AA. The control groups were 
individuals of African-American ancestry 
just like the patients used in the study. The 
diagnosis of sickle cell disease was based on 
the haemoglobin pattern on cellulose acetate 
electrophoresis. Family studies were 
consistent where available. The genotypes of 
the patients were divided as follows: 
a. SS - sickle cell anemia 14
b. S- sickle cell thalassaemia 4
c. SC-sickle cell hemoglobin C disease 2
Five patients were identified clinically and 
by physical diagnostic methods (such as 
radiography, etc.) to have skeletal 
complications due to sickle cell disease. All 
the other patients were asymptomatic for 
skeletal complications at the time blood 
samples were taken for the biochemical 
assays. The clinical history and routine liver 
function tests and urinalysis carried out on the 
experimental subjects including the control 
group showed that none of the patients or 
control subjects had liver, renal, or 
inflammatory disease during the time blood 
and urine samples were taken for the assays. 
The patients were attendees at sickle 
cell disease out-patient clinic. 
Blood samples: 
Blood samples were collected at the same time 
in the morning during clinic. Sera were 
separated from blood by centrifugation at 4 °C 
and were stored frozen at -60 °C until assayed. 
Assays were carried out within 1 to 2 weeks of 
storage. 
Assay of Biochemical markers of bone 
metabolism
a.  Determination of serum osteocalcin (S-
BGP):  Serum levels of osteocalcin (S-BGP) 
were determined in duplicate samples using an 
IRMA kit from CIS bio International, 
(GifSurYvette, France). The tracer is a 125I-
monoclonal antibody against human BGP. The 
monoclonal antibody used in this study is 
raised against human osteocalcin and therefore 
measured total serum osteocalcin protein 
levels. The serum concentration of osteocalcin 
was expressed as g/L.
b. Determination of serum bone-specific
alkaline phosphatase (S-b-AP): Serum b-AP 
protein level was determined with an IRMA 
(Tandem-R-OSTASE, Hybritech, San Diego, 
CA), using two monoclonal antibodies, 
specific for b-AP over liver alkaline 
phosphatase. Briefly, 100 µl of standard or 
serum and 100 µl tracer (100 nCi [125I] anti-b-
AP mouse monoclonal antibody) were added 
to beads coated with mouse monoclonal 
antibody directed to human b-AP. After 
incubation for 19  2 h at 4 oC, the solid beads 
were washed three times with detergent 
solution. Total and bound radioactivity was 
counted in a gamma-counter. The level of b-
AP protein is expressed as µg per liter. 
Statistical Analysis
The results are presented as means ± 
SD. Median values and range are included. 
The mean ± SD are compared, as applicable, 
by Student’s t-test. 
Results
There were no statistically significant 
differences in age between the groups. The 
results of the biochemical markers of bone 
formation, serum osteocalcin (S-BGP) and 
serum bone-specific alkaline phosphatase (b-
AP) are summarized in Table 1. The mean 
level of serum osteocalcin was not statistically
(p < 0.9) different from the control group. The 
concentration of bone-specific alkaline 
phosphatase protein was significantly higher in 
the patients with sickle cell disease than in 
control group (p < 0.05). The upper limit of the 
reference range (i.e. mean + 2 standard 
deviation, SD) of the control for the bone-
specific alkaline phosphatase was 25.5 µg/l. 
The upper limit of the reference ranges for 
serum osteocalcin (S-BGP) were exceeded by 
2/20 patients or 10 per cent and 11/20 patients 
or 55 per cent of all the sickle cell disease 
patients studied respectively. 
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Table  1: Summary of the biochemical markers in control group and patients with sickle cell 
Haemoglobinopathies






Range Mean ± SD (Median) Range






10.5 ± 7.5 (10) 6.0 – 15 16.9 ± 22.1 (17.0) 9.0 – 27.0 < 0.05
Serum Osteocalcin 
(BGP, µg/l)
20.3 ± 8.7 (16.6) 11.5– 37.3 19.9 ± 12.7 (16.2) 9.3 – 60.1 NS
SD*  = Standard Deviation  NS =Not Significant
Discussion 
Serum alkaline phosphatase is used 
extensively for the assessment of bone 
turnover in patients with various metabolic 
bone disorders, but its clinical use is often 
impaired by serum changes occurring in non-
bone alkaline phosphatase. In this study, we 
used the two-site immunoradiometric assay 
(IRMA) developed by Hybritech (Tandem-R 
Ostase) to determine the bone isoenzyme in 
sera of normal subjects and in patients with 
sickle cell haemoglobinopathies. With this 
IRMA, serum bone-specific alkaline 
phosphatase protein increased significantly in 
patients with sickle cell disease when 
compared with those in the normal healthy 
subject group. The results of bone-specific 
alkaline phosphatase total protein levels in this 
study agree with data obtained in patients with 
metabolic bone disease, showing increased 
serum bone-specific alkaline phosphatase 
(Duda et al, 1988).  Our data shows that serum 
bone-specific alkaline phosphatase total 
protein determination may be useful in early 
diagnosis of bone changes in sickle cell 
haemoglobinopathies, without any sign of 
hepatic disorder (Bolarin, 1983). There was 
no difference in the mean values of serum 
osteocalcin in both control group and patients 
with sickle cell haemoglobinopathies. The 
value of osteocalcin as a biochemical marker 
of bone matrix formation is unclear as 
fluctuation in circulating osteocalcin may only 
reflect changes in the equilibrium between 
bone matrix and bone (Bolarin, 1996; Duggan, 
2001). Osteocalcin is unstable in circulation 
and subject to variable vitamin K-dependent 
carboxylation. Because of the heterogeneity of 
circulating osteocalcin, different assays give 
differing results (Bolarin, 1996; Duggan, 
2001). 
In conclusion, we have shown that 
IRMA assay of serum bone-specific alkaline 
phosphatase total protein was more 
sensitive and specific than the determination of 
serum osteocalcin (S-BGP) to detect the 
increase in bone turnover due to bone 
remodeling in sickle cell haemoglobinopathies. 
The pilot data presented here also form the 
basis for further confirmatory studies leading 
to development of noninvasive biochemical 
markers to monitor skeletal complications in 
sickle cell disease. It may be useful to monitor 
the course of therapy of these complications in 
these patients, since it is characterized by 
increased sensitivity and organ specificity 
(Behr and Barnett, 1986).
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